Skip to content

US FDA hits Intas Pharma with warning letter; notes data integrity lapses at Ahmedabad plant

The regulator noted that visual inspectors manipulated particle and other defect counts on records to keep the finished product batches within rejection limits

Read More

​ The regulator noted that visual inspectors manipulated particle and other defect counts on records to keep the finished product batches within rejection limits The regulator noted that visual inspectors manipulated particle and other defect counts on records to keep the finished product batches within rejection limits  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish